Invasive carcinoma derived from branch duct-type IPMN may be a more aggressive neoplasm than that derived from main duct-type IPMN

Okabayashi,Takehiro; Shima,Yasuo; Kosaki,Takuhiro; Sumiyoshi,Tatsuaki; Kozuki,Akihito; Iiyama,Tastuo; Takezaki,Yuka; Kobayashi,Michiya; Nishimori,Isao; Ogawa,Yasuhiro; Hanazaki,Kazuhiro

doi:10.3892/ol.2013.1268

Invasive carcinoma derived from branch duct-type IPMN may be a more aggressive neoplasm than that derived from main duct-type IPMN

Authors:
- Takehiro Okabayashi
- Yasuo Shima
- Takuhiro Kosaki
- Tatsuaki Sumiyoshi
- Akihito Kozuki
- Tastuo Iiyama
- Yuka Takezaki
- Michiya Kobayashi
- Isao Nishimori
- Yasuhiro Ogawa
- Kazuhiro Hanazaki
View Affiliations

Affiliations: Department of Surgery, Kochi Health Sciences Center, Kochi 781-8555, Japan, Department of Gastroenterology and Hepatology, Kochi Medical School, Kochi University, Nankoku, Kochi 7838505, Japan, Department of Biostatistics, Kochi Medical School, Kochi University, Nankoku, Kochi 7838505, Japan, Department of Surgery, Kochi Medical School, Kochi University, Nankoku, Kochi 7838505, Japan, Department of Radiology, Kochi Medical School, Kochi University, Nankoku, Kochi 7838505, Japan
Published online on: March 21, 2013 https://doi.org/10.3892/ol.2013.1268
Pages: 1819-1825

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to evaluate the long‑term follow-up results of patients with intraductal papillary mucinous neoplasm (IPMN) and to estimate the degree of IPMN malignancy based on pathological and molecular features of resected specimens. The detection rate of IPMN has increased over the last decade; however, the management of this neoplasm remains controversial. This is particularly so for branch duct‑type IPMN, which carries a high potential for malignancy and risk of recurrence. We retrospectively reviewed a single institution's prospective pancreatic resection database to identify IPMN patients who underwent pancreatectomy with curative intent. The clinicopathological variables of 100 patients resected for IPMN were analyzed with a detailed review of histopathological results (borderline lesions, non-invasive carcinoma and invasive carcinoma) to determine the grade of IPMN malignancy based on transforming growth factor (TGF)-β/SMAD4 signaling. The incidence of malignant change was significantly higher in patients with main duct‑type IPMN (69.7%) compared with branch duct-type IPMN cases (17.9%). However, patients with an invasive carcinoma had a significantly worse outcome if it was derived from branch duct-type IPMN compared with those derived from main duct-type IPMN, and TGF-β mRNA expression was significantly increased in the former patient group. Immunohistochemistry also showed higher numbers of SMAD4-positive cells in patients with carcinoma derived from branch duct-type IPMN. Our results demonstrated that invasive carcinoma derived from branch duct-type IPMN is more aggressive than that derived from main duct-type IPMN, once invasive morphological change takes place. Determining TGF-β and/or SMAD4 status at initial diagnosis may be useful for stratifying IPMN patients into treatment regimens.

View Figures

View References

1	Tanaka M: Controversies in the management of pancreatic IPMN. Nat Rev Gastroenterol Hepatol. 8:56–60. 2011. View Article : Google Scholar : PubMed/NCBI
2	Mino-Kenudson M, Fernández-del Castillo C, Baba Y, et al: Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut. 60:1712–1720. 2011. View Article : Google Scholar : PubMed/NCBI
3	Fernández-del Castillo C and Adsay VN: Intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology. 139:708–713. 2010.
4	Loftus EV Jr, Olivares-Pakzad BA, Batts KP, et al: Intraductal papillary-mucinous tumors of the pancreas: clinicopathologic features, outcome, and nomenclature. Members of the Pancreas Clinic, and Pancreatic Surgeons of Mayo Clinic. Gastroenterology. 110:1909–1918. 1996. View Article : Google Scholar
5	Azar C, Van de Stadt J, Rickaert F, et al: Intraductal papillary and mucinous tumour of the pancreas. Clinical and therapeutic issues in 32 patients. Gut. 39:457–464. 1996. View Article : Google Scholar : PubMed/NCBI
6	Tanaka M, Chari S, Adsay V, et al International Association of Pancreatology: International Consensus Guidelines for management of intraductal papillary mucinous neoplasms andmucinous cystic neoplasms of the pancreas. Pancreatology. 6:17–32. 2006. View Article : Google Scholar
7	Salvia R, Fernández-del Castillo C, Bassi C, et al: Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg. 239:678–685. 2004. View Article : Google Scholar : PubMed/NCBI
8	Okabayashi T, Kobayashi M, Nishimori I, et al: Clinicopathological features and medical management of intraductal papillary mucinous neoplasms. J Gastroenterol Hepatol. 21:462–467. 2006. View Article : Google Scholar : PubMed/NCBI
9	Uehara H, Ishikawa O, Ikezawa K, et al: A natural course of main duct intraductal papillary mucinous neoplasm of the pancreas with lower likelihood of malignancy. Pancreas. 39:653–657. 2010. View Article : Google Scholar : PubMed/NCBI
10	Arlix A, Bournet B, Otal P, et al: Long-term clinical and imaging follow-up of nonoperated branch duct form of intraductal papillary mucinous neoplasms of the pancreas. Pancreas. 41:295–301. 2012. View Article : Google Scholar : PubMed/NCBI
11	Garcea G and Dennison AR: Branch-type intraductal papillary mucinous neoplasms: an update. Pancreatology. 11:336–342. 2011. View Article : Google Scholar : PubMed/NCBI
12	Okabayashi T, Nishimori I, Maeda H and Hanazaki K: Incidence of and predictive risk factors for intraductal papillary mucinous neoplasm of the pancreas with ordinary pancreatic cancer. J Clin Gastroenterol. 44:75–76. 2010. View Article : Google Scholar : PubMed/NCBI
13	Matthaei H, Norris AL, Tsiatis AC, et al: Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas. Ann Surg. 255:326–333. 2012. View Article : Google Scholar
14	Maguchi H, Tanno S, Mizuno N, et al: Natural history of branch duct intraductal papillary mucinous neoplasms of the pancreas: a multicenter study in Japan. Pancreas. 40:364–370. 2011. View Article : Google Scholar : PubMed/NCBI
15	Tanno S, Nakano Y, Nishikawa T, et al: Natural history of branch duct intraductal papillary-mucinous neoplasms of the pancreas without mural nodules: long-term follow-up results. Gut. 57:339–343. 2008. View Article : Google Scholar : PubMed/NCBI
16	Rautou PE, Lévy P, Vullierme MP, et al: Morphologic changes in branch duct intraductal papillary mucinous neoplasms of the pancreas: a midterm follow-up study. Clin Gastroenterol Hepatol. 6:807–814. 2008. View Article : Google Scholar : PubMed/NCBI
17	Hahn SA, Schutte M, Hoque AT, et al: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 271:350–353. 1996. View Article : Google Scholar : PubMed/NCBI
18	Yachida S, Jones S, Bozic I, et al: Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 467:1114–1117. 2010. View Article : Google Scholar : PubMed/NCBI
19	Kang MJ, Jang JY, Kim SJ, et al: Cyst growth rate predicts malignancy in patients with branch duct intraductal papillary mucinous neoplasms. Clin Gastroenterol Hepatol. 9:87–93. 2011. View Article : Google Scholar : PubMed/NCBI
20	Linton K, Hey Y, Dibben S, et al: Methods comparison for high-resolution transcriptional analysis of archival material on Affymetrix Plus 2.0 and Exon 1.0 microarrays. Biotechniques. 47:587–596. 2009. View Article : Google Scholar
21	Yang J, Ikezoe T, Nishioka C, et al: Long-term exposure of gastrointestinal stromal tumor cells to sunitinib induces epigenetic silencing of the PTEN gene. Int J Cancer. 130:959–966. 2012. View Article : Google Scholar : PubMed/NCBI
22	Rodriguez JR, Salvia R, Crippa S, et al: Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection. Gastroenterology. 133:72–79. 2007. View Article : Google Scholar : PubMed/NCBI
23	Salvia R, Crippa S, Falconi M, et al: Branch-duct intraductal papillary mucinous neoplasms of the pancreas: to operate or not to operate? Gut. 56:1086–1090. 2007. View Article : Google Scholar : PubMed/NCBI
24	Iacobuzio-Donahue CA, Klimstra DS, Adsay NV, et al: Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. Am J Pathol. 157:755–761. 2000. View Article : Google Scholar
25	Pedrazzoli S, Sperti C, Pasquali C, Bissoli S and Chierichetti F: Comparison of International Consensus Guidelines versus 18-FDG PET in detecting malignancy of intraductal papillary mucinous neoplasms of the pancreas. Ann Surg. 254:971–976. 2011. View Article : Google Scholar
26	Bierie B and Moses HL: Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer. 6:506–520. 2006. View Article : Google Scholar : PubMed/NCBI
27	Zavadil J and Böttinger EP: TGFbeta and epithelial-to-mesenchymal transitions. Oncogene. 24:5764–5774. 2005. View Article : Google Scholar : PubMed/NCBI
28	Bardeesy N, Cheng KH, Berger JH, et al: Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev. 20:3130–3146. 2006. View Article : Google Scholar : PubMed/NCBI
29	Braga M, Capretti G, Pecorelli N, et al: A prognostic score to predict major complications after pancreaticoduodenectomy. Ann Surg. 254:702–707. 2011. View Article : Google Scholar : PubMed/NCBI
30	Poultsides GA, Reddy S, Cameron JL, et al: Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas. Ann Surg. 251:470–476. 2010. View Article : Google Scholar